BCRX: BioCryst Pharmaceuticals Inc Company Profile & Statistics

BioCryst Pharmaceuticals Inc Profile

About

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

Info & Links

CEO

Charles Gayer

Headquarters

4505 EMPEROR BOULEVARD,SUITE 200
DURHAM, NC 27703, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

162

Employees

435

BioCryst Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization²

2.40B

Enterprise Value

2.79B

Enterprise Value/EBITDA(ttm)

8.25

Price to Earnings Ratio(ttm)

7.44

Price to Sales(ttm)

2.84

Price to Book(mrq)

Price to Cash(ytd)

7.99

Profitability

Gross Margin(ttm)

97.86%

Operating Margin(ttm)

33.27%

Profit Margin(ttm)

17.92%

Return on Equity(ttm)

-84.33%

Return on Invested Capital(ttm)

86.53%

Return on Assets(ttm)

61.35%

Income Statement

Revenue(ttm)

874.84M

Revenue Per Share(ttm)

3.49

Gross Profit(ttm)

855.76M

EBITDA(ttm)³

338.05M

Net Income Available to Common(ttm)

263.86M

Diluted EPS(ttm)

1.20

Share Statistics

Beta (5Y Monthly)

0.70

52-Week Change

41.43%

S&P 500 52-Week Change

27.10%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

250.80M

Dividend Yield

0.00%

Float⁴

238.01M

% Held by Insiders

5.10%

% Held by Institutions

85.88%

Balance Sheet

Total Cash(mrq)

274.95M

Total Cash Per Share(mrq)

1.10

Total Debt(mrq)

482.18M

Total Debt/Equity(mrq)

-404.68%

Current Ratio(mrq)

2.06%

Quick Ratio(mrq)

2.03%

Book Value Per Share(mrq)

-0.56

Cash Flow

Operating Cash Flow Per Share(ytd)

1.59

Free Cash Flow(ytd)

345.45M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

BCRX

BioCryst Pharmaceuticals Inc